The mechanism of action of vitamin B12 has not been established at a biochemical level. Evidence from both animal and microbiological studies has suggested that B12 may serve as a cofactor in the neogenesis of methyl groups or in the formation of deoxyribose (1, 2) . In such a capacity, B12 might be concerned with the synthesis of the methyl group of thymine (3) or of the pentose moiety of thymidylic and deoxycytidylic acids. In vitro studies of pernicous anemia marrow have indicated a direct stimulation by B12 of the incorporation of C14-formate into thymine (4) .
The partial remission in pernicious anemia produced by certain administered pyrimidines, notably orotic acid (5) , supports the hypothesis that B12 deficiency leads to a derangement of pyrimidine metabolism in man. Direct analyses of marrow components in pernicious anemia have demonstrated abnormal relationships of nucleic acids such that the ratio of ribonucleic acid (RNA) to deoxyribonucleic acid (DNA) is increased (6) . This report concerns studies of the cellular levels of three enzymes in pyrimidine biosynthesis using circulating erythrocytes and leukocytes from patients with pernicious anemia. EXPERIMENTAL PROCEDURE 1. Enzymatic studies. Assays were carried out on aspartate carbamyltransferase, dihydroorotase and dihydroorotic dehydrogenase ( Figure 1 ). The methods employed in separation of cells, sonication of leukocytes, hemolysis of erythrocytes and assay of the enzymes have been described in detail previously (7) . In brief, each assay depended on the incorporation of a C14 precursor of high specific activity into a product which was then isolated 
RESULTS

Aspartate carbamyltransferase
Aspartate carbamyltransferase, the first enzyme unique to pyrimidine biosynthesis, catalyzes the irreversible carbamylation of L-aspartic acid by carbamylphosphate to form carbamylaspartic acid ( Figure 1) (8) . A summary of the enzymatic activity of aspartate carbamyltransferase in normal erythrocytes and leukocytes and in the abnormal blood cells of 10 patients with pernicious anemia is presented in Figure 2A . Included for comparative purposes are studies of erythrocytes of one patient with the Di Guglielmo syndrome and the leukocytes of five patients with myelocytic leukemia. More detailed information concerning pyrimidine metabolism in leukemic cells is presented elsewhere (9 
Dihydroorotase
Dihydroorotase catalyzes the reversible cyclization of carbamylaspartic acid to form dihydroorotic acid ( Figure 1 ) (10). The biochemical characteristics of this enzyme in human blood cells have been described elsewhere (7) . In Figure 2B a summary is given of the enzymatic activities of dihydroorotase found in the erythrocytes and leukocytes of pernicious anemia in comparison with normal enzyme levels and in contrast to the values in the Di Guglielmo syndrome and myelocytic leukemia. Despite the variations in individual patients, the enzyme levels are again significantly increased (p < 0.01) in both erythrocytes and leukocytes. In several patients with pernicious anemia, leukocyte dihydroorotase was found to be within the range of myelocytic leukemia.
Dihydroorotic dehydrogenase
Dihydroorotic dehydrogenase catalyzes the reversible oxidation of dihydroorotic acid (DHO) to orotic acid (OA) as shown in Figure 1 (11). In previous studies this enzyme was found to be absent in mature erythrocytes and present in reproducible activity in leukocytes (7) . By cell fractionation studies the enzymatic activity was found to be largely in the cell nucleus. In Figure  2C the levels of dihydroorotic dehydrogenase activity are summarized for pernicious anemia, normal cells, Di Guglielmo syndrome and myelocytic leukemia. In the erythrocytes of pernicious anemia, dihydroorotic dehydrogenase could not be detected, as it can be, in normal erythrocytes. In contrast, the abnormal nucleated erythrocytes of the Di Guglielmo syndrome exhibited this activity. In the leukocytes of pernicious anemia, dihydroorotic dehydrogenase activity was normal, except for one deviant value. This is in contrast to the marked increase of activity noted in leukemic cells.
Reversibility of the enzyme abnormalities
All of the patients studied responded hematologically to parenteral B12 therapy. In two of the patients, follow-up studies were carried out after hematological remission was complete. Enzymatic activities of aspartate carbamyltransferase and dihydroorotase returned to normal ( Figure  3 ). The time course of this "enzymatic remission" was not followed because of the complications introduced by reticulocytosis and variations in cell age. (1) . In this way B12 40 cX might be concerned with the synthesis of thymine, n which has been reported to produce a partial re-30 I-mission in pernicious anemia when given in large > oral doses (14) . In marrow cells from pernicious 20 0 anemia studied in vitro the addition of B.2 to the plasma suspension has been shown to stimulate 0 the incorporation of C14-formate into thymine,°p resumably an indication of increased synthesis of DNA (4) . There is evidence that as a second function, B12 may be concerned with the synthesis of deoxyriboside or deoxyribotide derivatives of purine and pyrimidine bases (2) . Most of this mPM work has been carried out on microorganisms. 70 Partial remissions of pernicious anemia may be 6 produced by a large amount of a number of pyrimi- in its own biosynthesis (Figure 4 ). This controlling mechanism has been clearly shown to be operative in pyrimidine synthesis in bacteria by Yates and Pardee (16 A second type of negative feedback reaction has been described in pyrimidine synthesis in E. coli in which the product serves as a competitive inhibitor of the first enzyme in the biosynthetic sequence ( Figure 5 ) (17) . This is inhibition of enzyme activity rather than enzyme concentration. A similar controlling mechanism has also been described in purine synthesis (18 3. It is suggested that the enzyme abnormalities are most consistent with the pattern of "pyrimidine starvation" produced by vitamin B12 deficiency, the indirect evidence of a negative feedback control of enzyme concentrations in blood cells.
4. A second negative feedback control mechanism, the competitive inhibition of aspartate carbamyltransferase by cytidine-5'-phosphate, was confirmed in Escherichia coli but could not be demonstrated in erythrocytes or leukocytes.
